The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-NeuN Antibody Market Research Report 2024
Synopsis
NeuN is a reported synonym of the human protein 'RNA binding fox-1 homolog 3', encoded by the gene RBFOX3. The full protein is reported to be 312 amino acid residues in length. The NeuN antigen is a documented neuronal marker.
Global Anti-NeuN Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-NeuN Antibody market research.
Growing patient base, launch of novel anti-neuronal antibody drugs, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in revenue of the anti-neuronal antibody market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Anti-NeuN Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GeneTex
Novus Biologicals
Bioss
United States Biological
Thermo Fisher Scientific
Biorbyt
Synaptic Systems GmbH
LifeSpan BioSciences
NSJ Bioreagents
EpiGentek
Cell Signaling Technology
G Biosciences
Abcam
HUABIO
Enzo Life Sciences
RayBiotech
Merck
Bio-Rad
RevMAb Biosciences
Miltenyi Biotec
Leading Biology
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunofluorescence (IF)
Immunochemistry (IHC)
Western Blot (WB)
ELISA
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Anti-NeuN Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
NeuN is a reported synonym of the human protein 'RNA binding fox-1 homolog 3', encoded by the gene RBFOX3. The full protein is reported to be 312 amino acid residues in length. The NeuN antigen is a documented neuronal marker.
Global Anti-NeuN Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-NeuN Antibody market research.
Growing patient base, launch of novel anti-neuronal antibody drugs, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in revenue of the anti-neuronal antibody market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Anti-NeuN Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GeneTex
Novus Biologicals
Bioss
United States Biological
Thermo Fisher Scientific
Biorbyt
Synaptic Systems GmbH
LifeSpan BioSciences
NSJ Bioreagents
EpiGentek
Cell Signaling Technology
G Biosciences
Abcam
HUABIO
Enzo Life Sciences
RayBiotech
Merck
Bio-Rad
RevMAb Biosciences
Miltenyi Biotec
Leading Biology
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunofluorescence (IF)
Immunochemistry (IHC)
Western Blot (WB)
ELISA
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Anti-NeuN Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Anti-NeuN Antibody Market Overview
1.1 Product Overview and Scope of Anti-NeuN Antibody
1.2 Anti-NeuN Antibody Segment by Type
1.2.1 Global Anti-NeuN Antibody Market Value Comparison by Type (2023-2029)
1.2.2 Monoclonal
1.2.3 Polyclonal
1.3 Anti-NeuN Antibody Segment by Application
1.3.1 Global Anti-NeuN Antibody Market Value by Application: (2023-2029)
1.3.2 Immunofluorescence (IF)
1.3.3 Immunochemistry (IHC)
1.3.4 Western Blot (WB)
1.3.5 ELISA
1.3.6 Others
1.4 Global Anti-NeuN Antibody Market Size Estimates and Forecasts
1.4.1 Global Anti-NeuN Antibody Revenue 2018-2029
1.4.2 Global Anti-NeuN Antibody Sales 2018-2029
1.4.3 Global Anti-NeuN Antibody Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Anti-NeuN Antibody Market Competition by Manufacturers
2.1 Global Anti-NeuN Antibody Sales Market Share by Manufacturers (2018-2023)
2.2 Global Anti-NeuN Antibody Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Anti-NeuN Antibody Average Price by Manufacturers (2018-2023)
2.4 Global Anti-NeuN Antibody Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Anti-NeuN Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-NeuN Antibody, Product Type & Application
2.7 Anti-NeuN Antibody Market Competitive Situation and Trends
2.7.1 Anti-NeuN Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-NeuN Antibody Players Market Share by Revenue
2.7.3 Global Anti-NeuN Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-NeuN Antibody Retrospective Market Scenario by Region
3.1 Global Anti-NeuN Antibody Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Anti-NeuN Antibody Global Anti-NeuN Antibody Sales by Region: 2018-2029
3.2.1 Global Anti-NeuN Antibody Sales by Region: 2018-2023
3.2.2 Global Anti-NeuN Antibody Sales by Region: 2024-2029
3.3 Global Anti-NeuN Antibody Global Anti-NeuN Antibody Revenue by Region: 2018-2029
3.3.1 Global Anti-NeuN Antibody Revenue by Region: 2018-2023
3.3.2 Global Anti-NeuN Antibody Revenue by Region: 2024-2029
3.4 North America Anti-NeuN Antibody Market Facts & Figures by Country
3.4.1 North America Anti-NeuN Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Anti-NeuN Antibody Sales by Country (2018-2029)
3.4.3 North America Anti-NeuN Antibody Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-NeuN Antibody Market Facts & Figures by Country
3.5.1 Europe Anti-NeuN Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Anti-NeuN Antibody Sales by Country (2018-2029)
3.5.3 Europe Anti-NeuN Antibody Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-NeuN Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-NeuN Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Anti-NeuN Antibody Sales by Country (2018-2029)
3.6.3 Asia Pacific Anti-NeuN Antibody Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Anti-NeuN Antibody Market Facts & Figures by Country
3.7.1 Latin America Anti-NeuN Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Anti-NeuN Antibody Sales by Country (2018-2029)
3.7.3 Latin America Anti-NeuN Antibody Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Anti-NeuN Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-NeuN Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Anti-NeuN Antibody Sales by Country (2018-2029)
3.8.3 Middle East and Africa Anti-NeuN Antibody Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-NeuN Antibody Sales by Type (2018-2029)
4.1.1 Global Anti-NeuN Antibody Sales by Type (2018-2023)
4.1.2 Global Anti-NeuN Antibody Sales by Type (2024-2029)
4.1.3 Global Anti-NeuN Antibody Sales Market Share by Type (2018-2029)
4.2 Global Anti-NeuN Antibody Revenue by Type (2018-2029)
4.2.1 Global Anti-NeuN Antibody Revenue by Type (2018-2023)
4.2.2 Global Anti-NeuN Antibody Revenue by Type (2024-2029)
4.2.3 Global Anti-NeuN Antibody Revenue Market Share by Type (2018-2029)
4.3 Global Anti-NeuN Antibody Price by Type (2018-2029)
5 Segment by Application
5.1 Global Anti-NeuN Antibody Sales by Application (2018-2029)
5.1.1 Global Anti-NeuN Antibody Sales by Application (2018-2023)
5.1.2 Global Anti-NeuN Antibody Sales by Application (2024-2029)
5.1.3 Global Anti-NeuN Antibody Sales Market Share by Application (2018-2029)
5.2 Global Anti-NeuN Antibody Revenue by Application (2018-2029)
5.2.1 Global Anti-NeuN Antibody Revenue by Application (2018-2023)
5.2.2 Global Anti-NeuN Antibody Revenue by Application (2024-2029)
5.2.3 Global Anti-NeuN Antibody Revenue Market Share by Application (2018-2029)
5.3 Global Anti-NeuN Antibody Price by Application (2018-2029)
6 Key Companies Profiled
6.1 GeneTex
6.1.1 GeneTex Corporation Information
6.1.2 GeneTex Description and Business Overview
6.1.3 GeneTex Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.1.4 GeneTex Anti-NeuN Antibody Product Portfolio
6.1.5 GeneTex Recent Developments/Updates
6.2 Novus Biologicals
6.2.1 Novus Biologicals Corporation Information
6.2.2 Novus Biologicals Description and Business Overview
6.2.3 Novus Biologicals Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novus Biologicals Anti-NeuN Antibody Product Portfolio
6.2.5 Novus Biologicals Recent Developments/Updates
6.3 Bioss
6.3.1 Bioss Corporation Information
6.3.2 Bioss Description and Business Overview
6.3.3 Bioss Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bioss Anti-NeuN Antibody Product Portfolio
6.3.5 Bioss Recent Developments/Updates
6.4 United States Biological
6.4.1 United States Biological Corporation Information
6.4.2 United States Biological Description and Business Overview
6.4.3 United States Biological Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 United States Biological Anti-NeuN Antibody Product Portfolio
6.4.5 United States Biological Recent Developments/Updates
6.5 Thermo Fisher Scientific
6.5.1 Thermo Fisher Scientific Corporation Information
6.5.2 Thermo Fisher Scientific Description and Business Overview
6.5.3 Thermo Fisher Scientific Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Thermo Fisher Scientific Anti-NeuN Antibody Product Portfolio
6.5.5 Thermo Fisher Scientific Recent Developments/Updates
6.6 Biorbyt
6.6.1 Biorbyt Corporation Information
6.6.2 Biorbyt Description and Business Overview
6.6.3 Biorbyt Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Biorbyt Anti-NeuN Antibody Product Portfolio
6.6.5 Biorbyt Recent Developments/Updates
6.7 Synaptic Systems GmbH
6.6.1 Synaptic Systems GmbH Corporation Information
6.6.2 Synaptic Systems GmbH Description and Business Overview
6.6.3 Synaptic Systems GmbH Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Synaptic Systems GmbH Anti-NeuN Antibody Product Portfolio
6.7.5 Synaptic Systems GmbH Recent Developments/Updates
6.8 LifeSpan BioSciences
6.8.1 LifeSpan BioSciences Corporation Information
6.8.2 LifeSpan BioSciences Description and Business Overview
6.8.3 LifeSpan BioSciences Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.8.4 LifeSpan BioSciences Anti-NeuN Antibody Product Portfolio
6.8.5 LifeSpan BioSciences Recent Developments/Updates
6.9 NSJ Bioreagents
6.9.1 NSJ Bioreagents Corporation Information
6.9.2 NSJ Bioreagents Description and Business Overview
6.9.3 NSJ Bioreagents Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.9.4 NSJ Bioreagents Anti-NeuN Antibody Product Portfolio
6.9.5 NSJ Bioreagents Recent Developments/Updates
6.10 EpiGentek
6.10.1 EpiGentek Corporation Information
6.10.2 EpiGentek Description and Business Overview
6.10.3 EpiGentek Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.10.4 EpiGentek Anti-NeuN Antibody Product Portfolio
6.10.5 EpiGentek Recent Developments/Updates
6.11 Cell Signaling Technology
6.11.1 Cell Signaling Technology Corporation Information
6.11.2 Cell Signaling Technology Anti-NeuN Antibody Description and Business Overview
6.11.3 Cell Signaling Technology Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Cell Signaling Technology Anti-NeuN Antibody Product Portfolio
6.11.5 Cell Signaling Technology Recent Developments/Updates
6.12 G Biosciences
6.12.1 G Biosciences Corporation Information
6.12.2 G Biosciences Anti-NeuN Antibody Description and Business Overview
6.12.3 G Biosciences Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.12.4 G Biosciences Anti-NeuN Antibody Product Portfolio
6.12.5 G Biosciences Recent Developments/Updates
6.13 Abcam
6.13.1 Abcam Corporation Information
6.13.2 Abcam Anti-NeuN Antibody Description and Business Overview
6.13.3 Abcam Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Abcam Anti-NeuN Antibody Product Portfolio
6.13.5 Abcam Recent Developments/Updates
6.14 HUABIO
6.14.1 HUABIO Corporation Information
6.14.2 HUABIO Anti-NeuN Antibody Description and Business Overview
6.14.3 HUABIO Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.14.4 HUABIO Anti-NeuN Antibody Product Portfolio
6.14.5 HUABIO Recent Developments/Updates
6.15 Enzo Life Sciences
6.15.1 Enzo Life Sciences Corporation Information
6.15.2 Enzo Life Sciences Anti-NeuN Antibody Description and Business Overview
6.15.3 Enzo Life Sciences Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Enzo Life Sciences Anti-NeuN Antibody Product Portfolio
6.15.5 Enzo Life Sciences Recent Developments/Updates
6.16 RayBiotech
6.16.1 RayBiotech Corporation Information
6.16.2 RayBiotech Anti-NeuN Antibody Description and Business Overview
6.16.3 RayBiotech Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.16.4 RayBiotech Anti-NeuN Antibody Product Portfolio
6.16.5 RayBiotech Recent Developments/Updates
6.17 Merck
6.17.1 Merck Corporation Information
6.17.2 Merck Anti-NeuN Antibody Description and Business Overview
6.17.3 Merck Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Merck Anti-NeuN Antibody Product Portfolio
6.17.5 Merck Recent Developments/Updates
6.18 Bio-Rad
6.18.1 Bio-Rad Corporation Information
6.18.2 Bio-Rad Anti-NeuN Antibody Description and Business Overview
6.18.3 Bio-Rad Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Bio-Rad Anti-NeuN Antibody Product Portfolio
6.18.5 Bio-Rad Recent Developments/Updates
6.19 RevMAb Biosciences
6.19.1 RevMAb Biosciences Corporation Information
6.19.2 RevMAb Biosciences Anti-NeuN Antibody Description and Business Overview
6.19.3 RevMAb Biosciences Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.19.4 RevMAb Biosciences Anti-NeuN Antibody Product Portfolio
6.19.5 RevMAb Biosciences Recent Developments/Updates
6.20 Miltenyi Biotec
6.20.1 Miltenyi Biotec Corporation Information
6.20.2 Miltenyi Biotec Anti-NeuN Antibody Description and Business Overview
6.20.3 Miltenyi Biotec Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Miltenyi Biotec Anti-NeuN Antibody Product Portfolio
6.20.5 Miltenyi Biotec Recent Developments/Updates
6.21 Leading Biology
6.21.1 Leading Biology Corporation Information
6.21.2 Leading Biology Anti-NeuN Antibody Description and Business Overview
6.21.3 Leading Biology Anti-NeuN Antibody Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Leading Biology Anti-NeuN Antibody Product Portfolio
6.21.5 Leading Biology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-NeuN Antibody Industry Chain Analysis
7.2 Anti-NeuN Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-NeuN Antibody Production Mode & Process
7.4 Anti-NeuN Antibody Sales and Marketing
7.4.1 Anti-NeuN Antibody Sales Channels
7.4.2 Anti-NeuN Antibody Distributors
7.5 Anti-NeuN Antibody Customers
8 Anti-NeuN Antibody Market Dynamics
8.1 Anti-NeuN Antibody Industry Trends
8.2 Anti-NeuN Antibody Market Drivers
8.3 Anti-NeuN Antibody Market Challenges
8.4 Anti-NeuN Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
